Immunovative Therapies Ltd and its US subsidiary Mirror Biologics Inc. are testing a novel, T cell-based vaccination concept that might protect risk groups from new SARS-CoV-2 variants and any emerging viral pandemic in the future. However, therapies that significantly reduce the mortality rate of COVID-19 patients may be a cheaper way compared to vaccines to protect high-risk groups. UK researchers reported on the first therapy in mid-June.
Scientists map ulcerative colitis
Latest NewsScientists from Leuven, Rotterdam and San Diego have published a sequencing-based map of ulcerative colitis paving the way to new treatments.
COVID-19: Roche and Regeneron join forces
Latest NewsRoche and Regeneron have signed an manufacturing and distribution agreement on Regeneron’s Phase II therapeutic antibody for the treatment of COVID-19.
The role of investors in addressing AMR
OpinionAbigail Herron from Aviva Investors describes why AMR is a blind spot for investors and which action is needed to change it.
Aicuris to launch AiCubator to fight AMR
Latest NewsAntinfectives specialist AiCuris GmbH will launch the AiCubator, a new way to collaborate in anti-infectives and support novel approaches, at the 4th AMR Conference.
Cell-based vaccination vs mortality-reducing therapies
Latest NewsImmunovative Therapies Ltd and its US subsidiary Mirror Biologics Inc. are testing a novel, T cell-based vaccination concept that might protect risk groups from new SARS-CoV-2 variants and any emerging viral pandemic in the future. However, therapies that significantly reduce the mortality rate of COVID-19 patients may be a cheaper way compared to vaccines to protect high-risk groups. UK researchers reported on the first therapy in mid-June.
AI predicts mutations underlying neurological diseases
Latest NewsUsing data from more than 20,000 patients with neurological diseases, researchers have established an algorithm that predicts whether mutations in ion channels will cause disease.
F2G bags €50.8m financing to advance olorofim
Latest NewsUK-Austrian fungal infection specialist F2G Ltd has secured a €50.8m (US $60.8m) financing from new and existing investors.
Evotec receives $8.4m CARB-X funding
Latest NewsEvotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8.4m funding from CARB-X for co-development of a first-in-class antibiotic.
The new role of communications in times of corona
Latest NewsCOVID-19 has put life science research companies into the limelight. An Interview with Raimund Gabriel, founder and managing director MC Services AG, on the role of corporate communications in the corona crisis.
HistologiX appoints new Managing Director
AppointmentsBarbara McManus as the new managing director of Nottingham-based Contract Research Organisation (CRO) HistologiX.